お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:白血病治療薬の世界市場:種類別・男女別・年齢層別・診断方法別・治療手段別・薬物別・投与経路別・地域別の競争予測と市場機会 (2026年)
市場調査レポート
商品コード
998649

白血病治療薬の世界市場:種類別・男女別・年齢層別・診断方法別・治療手段別・薬物別・投与経路別・地域別の競争予測と市場機会 (2026年)

Global Leukemia Therapeutics Market, By Type, By Gender, By Age Groups, By Diagnosis, By Treatment, By Drugs, By Route of Administration, By Region, Competition Forecast & Opportunities, 2026

出版日: | 発行: TechSci Research | ページ情報: 英文 115 Pages | 納期: お問合せ

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.74円

こちらのレポートには、数時間(ご購入金額の10%)分のアナリストへの質問/追加調査サービスが含まれております。

白血病治療薬の世界市場:種類別・男女別・年齢層別・診断方法別・治療手段別・薬物別・投与経路別・地域別の競争予測と市場機会 (2026年)
出版日: 2021年04月01日
発行: TechSci Research
ページ情報: 英文 115 Pages
納期: お問合せ
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の白血病治療薬の市場規模は、2020年に185億8423万米ドルに達し、予測期間中に7.47%のCAGRで成長すると予想されています。

市場の主な促進要因として、白血病患者の増加や人口高齢化の進展、血液がん検査の分野での技術革新、予防医療に対する関心増大などが挙げられます。疾患別に見ると、慢性リンパ性白血病が全体の34.52%を占めています。薬物別では、チロシンキナーゼ阻害剤が有効性の高さや副作用の少なさを武器に、市場の支配権を握っています。地域別に見ると、北米諸国が世界市場の3分の1を占めています。

当レポートでは、世界の白血病治療薬の市場について分析し、全体的な市場規模の動向見通しや市場シェア構造 (種類別・男女別・年齢層別・診断方法別・治療手段別・薬物別・投与経路別)、地域別・主要国の詳細動向、主な市場促進・抑制要因、企業間の市場競争構造、主要企業のプロファイル、今後の市場成長の方向性などを調査しております。

目次

第1章 製品概要

第2章 分析方法

第3章 世界の白血病治療薬市場に対するCOVID-19の影響

第4章 エグゼクティブサマリー

第5章 顧客側の見解

  • ブランド認知度
  • 世界の白血病治療薬市場の促進要因
  • アンメットニーズと課題

第6章 世界の白血病治療薬市場:将来展望

  • 市場規模とその予測
    • 金額ベース
  • 市場シェアとその予測
    • 種類別(慢性リンパ性白血病、急性骨髄性白血病、慢性骨髄性白血病、急性リンパ性白血病、その他)
    • 男女別(男性、女性)
    • 年齢層別(0~15歳、15~30歳、30~50歳、50歳以上)
    • 診断方法別(血液検査、生検、健康診断、画像診断)
    • 治療手段別(化学療法、幹細胞移植、免疫療法、標的療法、その他)
    • 薬物別(代謝拮抗剤、ホルモン(コルチコステロイド)、チロシンキナーゼ阻害剤、モノクローナル抗体、その他)
    • 投与経路別(経口、非経口)
    • 企業別 (2020年)
    • 地域別

第7章 北米の白血病治療薬市場:将来展望

  • 市場規模とその予測
  • 市場シェアとその予測
  • 北米:国別分析
    • 米国
    • カナダ
    • メキシコ

第8章 欧州の白血病治療薬市場:将来展望

  • 市場規模とその予測
  • 市場シェアとその予測
  • 欧州:国別分析
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン

第9章 アジア太平洋の白血病治療薬市場:将来展望

  • 市場規模とその予測
  • 市場シェアとその予測
  • アジア太平洋:国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第10章 南米の白血病治療薬市場:将来展望

  • 市場規模とその予測
  • 市場シェアとその予測
  • 南米:国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第11章 中東・アフリカの白血病治療薬市場:将来展望

  • 市場規模とその予測
  • 市場シェアとその予測
  • 中東・アフリカ:国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦 (UAE)

第12章 市場力学

  • 促進要因
  • 課題

第13章 市場の動向

第14章 治験の分析

第15章 競合情勢

  • 市場競争の見通し
  • 企業プロファイル(大手企業)
    • Novartis AG
    • AbbVie Inc.
    • Roche Holding AG
    • Amgen Inc.
    • AstraZeneca PLC
    • Pfizer Inc.
    • Merck & Company Inc.
    • Eli Lilly and Company Ltd.
    • Bristol-Myers Squibb Company
    • Gilead Sciences Inc.
    • Astellas Pharma Inc.
    • Takeda Pharmaceutical Company Ltd.
    • Stemline Therapeutics Inc.
    • iCell Gene therapeutics
    • Otsuka Holdings Company Ltd.

第16章 戦略提言

第17章 TechSci Researchについて、免責事項

図表

List of Figures

  • Figure 1: Global Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 2: Global Leukemia Therapeutics Market Share, By Type, 2016-2026F
  • Figure 3: Global Leukemia Therapeutics Market Share, By Gender, 2016-2026F
  • Figure 4: Global Leukemia Therapeutics Market Share, By Age Groups, 2016-2026F
  • Figure 5: Global Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
  • Figure 6: Global Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
  • Figure 7: Global Leukemia Therapeutics Market Share, By Drug, 2016-2026F
  • Figure 8: Global Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
  • Figure 9: Global Leukemia Therapeutics Market, Market Map, By Region, By Value, 2016-2026F
  • Figure 10: North America Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 11: North America Leukemia Therapeutics Market Share, By Type, 2016-2026F
  • Figure 12: North America Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
  • Figure 13: North America Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
  • Figure 14: North America Leukemia Therapeutics Market Share, By Drug, 2016-2026F
  • Figure 15: North America Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
  • Figure 16: North America Leukemia Therapeutics Market Share, By Country, 2016-2026F
  • Figure 17: United States Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 18: United States Leukemia Therapeutics Market Share, By Type, 2016-2026F
  • Figure 19: United States Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
  • Figure 20: United States Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
  • Figure 21: United States Leukemia Therapeutics Market Share, By Drug, 2016-2026F
  • Figure 22: United States Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
  • Figure 23: Canada Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 24: Canada Leukemia Therapeutics Market Share, By Type, 2016-2026F
  • Figure 25: Canada Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
  • Figure 26: Canada Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
  • Figure 27: Canada Leukemia Therapeutics Market Share, By Drug, 2016-2026F
  • Figure 28: Canada Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
  • Figure 29: Mexico Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 30: Mexico Leukemia Therapeutics Market Share, By Type, 2016-2026F
  • Figure 31: Mexico Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
  • Figure 32: Mexico Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
  • Figure 33: Mexico Leukemia Therapeutics Market Share, By Drug, 2016-2026F
  • Figure 34: Mexico Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
  • Figure 35: Europe Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 36: Europe Leukemia Therapeutics Market Share, By Type, 2016-2026F
  • Figure 37: Europe Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
  • Figure 38: Europe Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
  • Figure 39: Europe Leukemia Therapeutics Market Share, By Drug, 2016-2026F
  • Figure 40: Europe Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
  • Figure 41: Europe Leukemia Therapeutics Market Share, By Country, 2016-2026F
  • Figure 42: Germany Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 43: Germany Leukemia Therapeutics Market Share, By Type, 2016-2026F
  • Figure 44: Germany Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
  • Figure 45: Germany Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
  • Figure 46: Germany Leukemia Therapeutics Market Share, By Drug, 2016-2026F
  • Figure 47: Germany Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
  • Figure 48: France Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 49: France Leukemia Therapeutics Market Share, By Type, 2016-2026F
  • Figure 50: France Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
  • Figure 51: France Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
  • Figure 52: France Leukemia Therapeutics Market Share, By Drug, 2016-2026F
  • Figure 53: France Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
  • Figure 54: United Kingdom Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 55: United Kingdom Leukemia Therapeutics Market Share, By Type, 2016-2026F
  • Figure 56: United Kingdom Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
  • Figure 57: United Kingdom Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
  • Figure 58: United Kingdom Leukemia Therapeutics Market Share, By Drug, 2016-2026F
  • Figure 59: United Kingdom Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
  • Figure 60: Italy Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 61: Italy Leukemia Therapeutics Market Share, By Type, 2016-2026F
  • Figure 62: Italy Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
  • Figure 63: Italy Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
  • Figure 64: Italy Leukemia Therapeutics Market Share, By Drug, 2016-2026F
  • Figure 65: Italy Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
  • Figure 66: Spain Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 67: Spain Leukemia Therapeutics Market Share, By Type, 2016-2026F
  • Figure 68: Spain Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
  • Figure 69: Spain Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
  • Figure 70: Spain Leukemia Therapeutics Market Share, By Drug, 2016-2026F
  • Figure 71: Spain Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
  • Figure 72: Asia-Pacific Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 73: Asia-Pacific Leukemia Therapeutics Market Share, By Type, 2016-2026F
  • Figure 74: Asia-Pacific Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
  • Figure 75: Asia-Pacific Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
  • Figure 76: Asia-Pacific Leukemia Therapeutics Market Share, By Drug, 2016-2026F
  • Figure 77: Asia-Pacific Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
  • Figure 78: Asia-Pacific Leukemia Therapeutics Market Share, By Country, 2016-2026F
  • Figure 79: China Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 80: China Leukemia Therapeutics Market Share, By Type, 2016-2026F
  • Figure 81: China Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
  • Figure 82: China Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
  • Figure 83: China Leukemia Therapeutics Market Share, By Drug, 2016-2026F
  • Figure 84: China Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
  • Figure 85: India Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 86: India Leukemia Therapeutics Market Share, By Type, 2016-2026F
  • Figure 87: India Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
  • Figure 88: India Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
  • Figure 89: India Leukemia Therapeutics Market Share, By Drug, 2016-2026F
  • Figure 90: India Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
  • Figure 91: Japan Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 92: Japan Leukemia Therapeutics Market Share, By Type, 2016-2026F
  • Figure 93: Japan Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
  • Figure 94: Japan Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
  • Figure 95: Japan Leukemia Therapeutics Market Share, By Drug, 2016-2026F
  • Figure 96: Japan Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
  • Figure 97: South Korea Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 98: South Korea Leukemia Therapeutics Market Share, By Type, 2016-2026F
  • Figure 99: South Korea Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
  • Figure 100: South Korea Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
  • Figure 101: South Korea Leukemia Therapeutics Market Share, By Drug, 2016-2026F
  • Figure 102: South Korea Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
  • Figure 103: Australia Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 104: Australia Leukemia Therapeutics Market Share, By Type, 2016-2026F
  • Figure 105: Australia Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
  • Figure 106: Australia Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
  • Figure 107: Australia Leukemia Therapeutics Market Share, By Drug, 2016-2026F
  • Figure 108: Australia Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
  • Figure 109: South America Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 110: South America Leukemia Therapeutics Market Share, By Type, 2016-2026F
  • Figure 111: South America Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
  • Figure 112: South America Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
  • Figure 113: South America Leukemia Therapeutics Market Share, By Drug, 2016-2026F
  • Figure 114: South America Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
  • Figure 115: South America Leukemia Therapeutics Market Share, By Country, 2016-2026F
  • Figure 116: Brazil Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 117: Brazil Leukemia Therapeutics Market Share, By Type, 2016-2026F
  • Figure 118: Brazil Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
  • Figure 119: Brazil Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
  • Figure 120: Brazil Leukemia Therapeutics Market Share, By Drug, 2016-2026F
  • Figure 121: Brazil Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
  • Figure 122: Argentina Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 123: Argentina Leukemia Therapeutics Market Share, By Type, 2016-2026F
  • Figure 124: Argentina Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
  • Figure 125: Argentina Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
  • Figure 126: Argentina Leukemia Therapeutics Market Share, By Drug, 2016-2026F
  • Figure 127: Argentina Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
  • Figure 128: Colombia Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 129: Colombia Leukemia Therapeutics Market Share, By Type, 2016-2026F
  • Figure 130: Colombia Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
  • Figure 131: Colombia Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
  • Figure 132: Colombia Leukemia Therapeutics Market Share, By Drug, 2016-2026F
  • Figure 133: Colombia Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
  • Figure 134: Middle East and Africa Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 135: Middle East and Africa Leukemia Therapeutics Market Share, By Type, 2016-2026F
  • Figure 136: Middle East and Africa Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
  • Figure 137: Middle East and Africa Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
  • Figure 138: Middle East and Africa Leukemia Therapeutics Market Share, By Drug, 2016-2026F
  • Figure 139: Middle East and Africa Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
  • Figure 140: Middle East and Africa Leukemia Therapeutics Market Share, By Country, 2016-2026F
  • Figure 141: South Africa Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 142: South Africa Leukemia Therapeutics Market Share, By Type, 2016-2026F
  • Figure 143: South Africa Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
  • Figure 144: South Africa Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
  • Figure 145: South Africa Leukemia Therapeutics Market Share, By Drug, 2016-2026F
  • Figure 146: South Africa Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
  • Figure 147: Saudi Arabia Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 148: Saudi Arabia Leukemia Therapeutics Market Share, By Type, 2016-2026F
  • Figure 149: Saudi Arabia Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
  • Figure 150: Saudi Arabia Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
  • Figure 151: Saudi Arabia Leukemia Therapeutics Market Share, By Drug, 2016-2026F
  • Figure 152: Saudi Arabia Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
  • Figure 153: UAE Leukemia Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 154: UAE Leukemia Therapeutics Market Share, By Type, 2016-2026F
  • Figure 155: UAE Leukemia Therapeutics Market Share, By Diagnosis, 2016-2026F
  • Figure 156: UAE Leukemia Therapeutics Market Share, By Treatment, 2016-2026F
  • Figure 157: UAE Leukemia Therapeutics Market Share, By Drug, 2016-2026F
  • Figure 158: UAE Leukemia Therapeutics Market Share, By Route of Administration, 2016-2026F
目次
Product Code: 4534

Title:
Global Leukemia Therapeutics Market, By Type (Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Others), By Gender (Male, Female), By Age Groups (0-15, 15-30, 30-50, 50+), By Diagnosis (Blood Test, Biopsy, Physical Exam, Imaging), By Treatment (Chemotherapy, Stem Cell Transplantation, Immunotherapy, Targeted Therapy, Others), By Drugs (Tyrosine Kinase Inhibitors, Antimetabolites, Hormones (Corticosteroids), Monoclonal Antibodies, Others), By Route of Administration (Oral, Parenteral), By Region, Competition Forecast & Opportunities, 2026.

Global leukemia therapeutics market was valued USD18584.23 Million in 2020 and is expected to grow at a CAGR of 7.47% during the forecast period. The global leukemia therapeutics market is driven by the technological advancements and innovations in the field of blood cancer testing on account of the growing number of patients suffering from leukemia. Additionally, growing awareness among the population pertaining to adoption of preventive healthcare is further expected to propel the market during forecast period. Supportive government initiatives and policies for promoting cancer awareness are anticipated to fuel the market growth until 2026.

Leukemia or blood cancer is the cancer of blood forming tissues: bone marrow and lymphatic system. As the name suggests, it affects the leucocytes or white blood cells. In this type of cancer, the DNA of leucocytes gets damaged as a result of which they grow and divide uncontrollably. These cells keep on growing and start accumulating, thereby preventing the healthy white blood cells from growing and functioning.

The global leukemia therapeutics market can be segmented based on type, gender, age groups, diagnosis, treatment, drugs, route of administration, company and region. Based on type, the market can be bifurcated into chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia and others. The chronic lymphocytic leukemia segment led the market in 2020 with share of 34.52%. This can be accredited to the rising geriatric population and increasing funding for research and the development of new cancer therapies. The male and geriatric population are mostly affected by leukemia. The most common diagnosis method of this type of cancer is biopsy whereas, imaging is expected to grow in the near future owing to the improvement and adoption of technology across the globe. Amongst the drug segment, tyrosine kinase inhibitors dominated the global leukemia therapeutic market owing to their greater efficacy and fewer side effects as compared to the rest. Most of the treatments and drugs are administered via injections via intravenous, subcutaneous, intramuscular and intrathecal modes.

Regionally, the leukemia therapeutics market has been segmented into Asia-Pacific, North America, South America, Europe, and Middle East & Africa. Among these regions, North America is expected to dominate the market with one-third share during the forecast period. This can be attributed to the presence of a large geriatric population base. Besides, the presence of key players in the region is further expected to propel the market over 2026.

Major players operating in the global leukemia therapeutics market include Novartis AG, AbbVie Inc., Roche Holding AG, Amgen Inc., AstraZeneca PLC, Pfizer Inc., Merck & Company Inc., Eli Lilly and Company Ltd., Bristol-Myers Squibb Company, Gilead Sciences Inc., Astellas Pharma Inc., Takeda Pharmaceutical Company Ltd., Stemline Therapeutics Inc., iCell Gene Therapeutics, Otsuka Holdings Company Ltd. The companies operating in the market are using organic strategies such as product launches, mergers and collaborations to boost their share. For instance, in September 2020, Gilead Sciences Inc. completed the acquisition of Immunomedics Inc., which was one of the biggest acquisition in 2020.

Years considered for this report:

Historical Years: 2016-2019

Base Year: 2020

Estimated Year: 2021

Forecast Period: 2022- 2026

Objective of the Study:

  • To analyze historical growth in market size of global leukemia therapeutics market from 2016 to 2020.
  • . To estimate and forecast the market size of global leukemia therapeutics market from 2021 to 2026 and growth rate until 2026.
  • To classify and forecast global leukemia therapeutics market based on factor, severity, blood cell, age groups, gender, treatment, diagnosis, route of administration, drugs, company and regional distribution.
  • To identify drivers and challenges for global leukemia therapeutics market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global leukemia therapeutics market.
  • To identify and analyze the profiles of leading players operating in global leukemia therapeutics market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufacturers, distribution channels and presence of all major players across the globe.

TechSci Research calculated the market size of global leukemia therapeutics market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated them through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Leukemia drugs manufacturers, suppliers, distributors and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to leukemia therapeutics
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers and partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global leukemia therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Global Leukemia Therapeutics Market, By Type:

Chronic Lymphocytic Leukemia

Acute Myeloid Leukemia

Chronic Myeloid Leukemia

Acute Lymphocytic Leukemia

Others

  • Global Leukemia Therapeutics Market, By Gender:

Male

Female

  • Global Leukemia Therapeutics Market, By Age Groups:

0-15

15-30

30-50

50+

  • Global Leukemia Therapeutics Market, By Diagnosis:

Blood test

Biopsy

Physical Exam

Imaging

  • Global Leukemia Therapeutics Market, By Treatment:

Chemotherapy

Stem Cell Transplantation

Immunotherapy

Targeted Therapy

Others

  • Global Leukemia Therapeutics Market, By Drugs:

Tyrosine Kinase Inhibitors

Antimetabolites

Hormones (Corticosteroids)

Monoclonal Antibodies

Others

  • Global Leukemia Therapeutics Market, By Route of Administration:

Oral

Parenteral

  • Global Leukemia Therapeutics Market, By Region:

North America

  • United States
  • Canada
  • Mexico

Europe

  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain

Asia-Pacific

  • China
  • Japan
  • India
  • South Korea
  • Australia

Middle East & Africa

  • South Africa
  • Saudi Arabia
  • UAE

South America

  • Brazil
  • Argentina
  • Colombia

Competitive Landscape:

Company Profiles: Detailed analysis of the major companies present in global leukemia therapeutics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information:

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Leukemia Therapeutics Market

4. Executive Summary

5. Voice of Customer

  • 5.1. Brand Awareness
  • 5.2. Factors driving Global Leukemic Therapeutics Market
  • 5.3. Unmet Needs and Challenges

6. Global Leukemia Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type (Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Others)
    • 6.2.2. By Gender (Male, Female)
    • 6.2.3. By Age Groups (0-15, 15-30, 30-50, 50+)
    • 6.2.4. By Diagnosis (Blood Test, Biopsy, Physical Exam, Imaging)
    • 6.2.5. By Treatment (Chemotherapy, Stem Cell Transplantation, Immunotherapy, Targeted Therapy, Others)
    • 6.2.6. By Drugs (Antimetabolites, Hormones (Corticosteroids), Tyrosine Kinase Inhibitors, Monoclonal Antibodies, Others)
    • 6.2.7. By Route of Administration (Oral, Parenteral)
    • 6.2.8. By Company (2020)
    • 6.2.9. By Region

7. North America Leukemia Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Diagnosis
    • 7.2.3. By Treatment
    • 7.2.4. By Drugs
    • 7.2.5. By Route of Administration
    • 7.2.6. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Leukemia Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Diagnosis
        • 7.3.1.2.3. By Treatment
        • 7.3.1.2.4. By Drugs
        • 7.3.1.2.5. By Route of Administration
    • 7.3.2. Canada Leukemia Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Diagnosis
        • 7.3.2.2.3. By Treatment
        • 7.3.2.2.4. By Drugs
        • 7.3.2.2.5. By Route of Administration
    • 7.3.3. Mexico Leukemia Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Diagnosis
        • 7.3.3.2.3. By Treatment
        • 7.3.3.2.4. By Drugs
        • 7.3.3.2.5. By Route of Administration

8. Europe Leukemia Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Diagnosis
    • 8.2.3. By Treatment
    • 8.2.4. By Drugs
    • 8.2.5. By Route of Administration
    • 8.2.6. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. Germany Leukemia Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Diagnosis
        • 8.3.1.2.3. By Treatment
        • 8.3.1.2.4. By Drugs
        • 8.3.1.2.5. By Route of Administration
    • 8.3.2. France Leukemia Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Diagnosis
        • 8.3.2.2.3. By Treatment
        • 8.3.2.2.4. By Drugs
        • 8.3.2.2.5. By Route of Administration
    • 8.3.3. United Kingdom Leukemia Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Diagnosis
        • 8.3.3.2.3. By Treatment
        • 8.3.3.2.4. By Drugs
        • 8.3.3.2.5. By Route of Administration
    • 8.3.4. Italy Leukemia Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Diagnosis
        • 8.3.4.2.3. By Treatment
        • 8.3.4.2.4. By Drugs
        • 8.3.4.2.5. By Route of Administration
    • 8.3.5. Spain Leukemia Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Diagnosis
        • 8.3.5.2.3. By Treatment
        • 8.3.5.2.4. By Drugs
        • 8.3.5.2.5. By Route of Administration

9. Asia-Pacific Leukemia Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Diagnosis
    • 9.2.3. By Treatment
    • 9.2.4. By Drugs
    • 9.2.5. By Route of Administration
    • 9.2.6. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Leukemia Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Diagnosis
        • 9.3.1.2.3. By Treatment
        • 9.3.1.2.4. By Drugs
        • 9.3.1.2.5. By Route of Administration
    • 9.3.2. India Leukemia Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Diagnosis
        • 9.3.2.2.3. By Treatment
        • 9.3.2.2.4. By Drugs
        • 9.3.2.2.5. By Route of Administration
    • 9.3.3. Japan Leukemia Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Diagnosis
        • 9.3.3.2.3. By Treatment
        • 9.3.3.2.4. By Drugs
        • 9.3.3.2.5. By Route of Administration
    • 9.3.4. South Korea Leukemia Therapeutics Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Type
        • 9.3.4.2.2. By Diagnosis
        • 9.3.4.2.3. By Treatment
        • 9.3.4.2.4. By Drugs
        • 9.3.4.2.5. By Route of Administration
    • 9.3.5. Australia Leukemia Therapeutics Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Type
        • 9.3.5.2.2. By Diagnosis
        • 9.3.5.2.3. By Treatment
        • 9.3.5.2.4. By Drugs
        • 9.3.5.2.5. By Route of Administration

10. South America Leukemia Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Diagnosis
    • 10.2.3. By Treatment
    • 10.2.4. By Drugs
    • 10.2.5. By Route of Administration
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Leukemia Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Diagnosis
        • 10.3.1.2.3. By Treatment
        • 10.3.1.2.4. By Drugs
        • 10.3.1.2.5. By Route of Administration
    • 10.3.2. Argentina Leukemia Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Diagnosis
        • 10.3.2.2.3. By Treatment
        • 10.3.2.2.4. By Drugs
        • 10.3.2.2.5. By Route of Administration
    • 10.3.3. Colombia Leukemia Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Diagnosis
        • 10.3.3.2.3. By Treatment
        • 10.3.3.2.4. By Drugs
        • 10.3.3.2.5. By Route of Administration

11. Middle East and Africa Leukemia Therapeutics Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Type
    • 11.2.2. By Diagnosis
    • 11.2.3. By Treatment
    • 11.2.4. By Drugs
    • 11.2.5. By Route of Administration
    • 11.2.6. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Leukemia Therapeutics Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Type
        • 11.3.1.2.2. By Diagnosis
        • 11.3.1.2.3. By Treatment
        • 11.3.1.2.4. By Drugs
        • 11.3.1.2.5. By Route of Administration
    • 11.3.2. Saudi Arabia Leukemia Therapeutics Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Type
        • 11.3.2.2.2. By Diagnosis
        • 11.3.2.2.3. By Treatment
        • 11.3.2.2.4. By Drugs
        • 11.3.2.2.5. By Route of Administration
    • 11.3.3. UAE Leukemia Therapeutics Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Type
        • 11.3.3.2.2. By Diagnosis
        • 11.3.3.2.3. By Treatment
        • 11.3.3.2.4. By Drugs
        • 11.3.3.2.5. By Route of Administration

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Clinical Trial Analysis

15. Competitive Landscape

  • 15.1. Competition Outlook
  • 15.2. Players Profiled (Leading Companies)
    • 15.2.1. Novartis AG
    • 15.2.2. AbbVie Inc.
    • 15.2.3. Roche Holding AG
    • 15.2.4. Amgen Inc.
    • 15.2.5. AstraZeneca PLC
    • 15.2.6. Pfizer Inc.
    • 15.2.7. Merck & Company Inc.
    • 15.2.8. Eli Lilly and Company Ltd.
    • 15.2.9. Bristol-Myers Squibb Company
    • 15.2.10. Gilead Sciences Inc.
    • 15.2.11. Astellas Pharma Inc.
    • 15.2.12. Takeda Pharmaceutical Company Ltd.
    • 15.2.13. Stemline Therapeutics Inc.
    • 15.2.14. iCell Gene therapeutics
    • 15.2.15. Otsuka Holdings Company Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.